Sex Differences in Long-Term Safety and Tolerability of Growth Hormone (GH) Replacement Therapy in GH Deficient Adults
Authors' conclusion
Data obtained from the Dutch National Registry of GH Treatment in Adults indicate that GHD women might be treated suboptimally, reflected as lower IGF-1 status and lower GHRT tolerability, leading to more frequent changes in treatment regimen but not discontinuation of GHRT. Regarding long-term safety, we found a higher risk for development of malignancies in GHD men.
Study context
- Population
- Dutch adults with growth hormone deficient (GHD) treated with GH replacement therapy, Dutch National Registry of GH Treatment in Adults
- Participants
- 1,251 vs 1,335
- Exposure
- GHD women vs men treated with GHRT
- Womenn = 1,251
- Menn = 1,335reference
- Outcome
- IGF-1 SD scores during treatment
- Follow-up
- During treatment
Methodological detailsnationwide registry
- Nationwide registry
Main finding
As reported in the abstract
- Women vs Men: P < 0.001
- Men vs Women: P < 0.001
- Sensitivity analysis
Observational data: associations, not effects.
Further findings
GHRT discontinuation
- Both sexes equally discontinued GHRT (in percentages)
Safety
| Outcome | P value |
|---|---|
| Adverse eventsMore AEs in women, especially fluid retention symptoms | P < 0.001 |
| Dose reduction or temporary stop of GHRTMore often in women | P = 0.001 |
| Malignant neoplasmsHigher risk in men | P = 0.012 |
T2D, benign neoplasms, tumor recurrence
- Risk equal in both sexes
Original publication
Sex Differences in Long-Term Safety and Tolerability of GH Replacement Therapy in GH Deficient Adults. J Clin Endocrinol Metab. Published 18 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →